Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review.

Cobelens F, van Kampen S, Ochodo E, Atun R, Lienhardt C.

PLoS Med. 2012;9(12):e1001358. doi: 10.1371/journal.pmed.1001358. Epub 2012 Dec 18. Review.

2.
3.

Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.

Briggs MA, Emerson C, Modi S, Taylor NK, Date A.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S297-305. doi: 10.1097/QAI.0000000000000497. Review.

PMID:
25768869
4.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
5.

Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews.

Adams LV, Talbot EA, Odato K, Blunt H, Steingart KR.

BMC Infect Dis. 2014 May 21;14:281. doi: 10.1186/1471-2334-14-281. Review.

6.

Tuberculosis contact screening and isoniazid preventive therapy in a South Indian district: operational issues for programmatic consideration.

Pothukuchi M, Nagaraja SB, Kelamane S, Satyanarayana S, Shashidhar, Babu S, Dewan P, Wares F.

PLoS One. 2011;6(7):e22500. doi: 10.1371/journal.pone.0022500. Epub 2011 Jul 22.

7.

Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda.

Shrestha RK, Mugisha B, Bunnell R, Mermin J, Hitimana-Lukanika C, Odeke R, Madra P, Adatu F, Blandford JM.

Int J Tuberc Lung Dis. 2006 Jun;10(6):656-62.

PMID:
16776453
8.

Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting.

Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E.

Thorax. 2013 Mar;68(3):247-55. doi: 10.1136/thoraxjnl-2011-200933. Epub 2012 Jun 20.

PMID:
22717944
9.

Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries.

Tudor Car L, van-Velthoven MH, Brusamento S, Elmoniry H, Car J, Majeed A, Atun R.

Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008741. doi: 10.1002/14651858.CD008741.pub2. Review.

PMID:
21678382
10.

HIV-related tuberculosis: how well are we doing with current control efforts?

Maher D, Borgdorff M, Boerma T.

Int J Tuberc Lung Dis. 2005 Jan;9(1):17-24.

PMID:
15675545
11.

The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.

Sutton BS, Arias MS, Chheng P, Eang MT, Kimerling ME.

Int J Tuberc Lung Dis. 2009 Jun;13(6):713-8.

PMID:
19460246
12.

Survey of isoniazid preventive therapy in South Africa, 2011.

Chehab JC, Vilakazi-Nhlapo K, Vranken P, Peters A, Klausner JD.

Int J Tuberc Lung Dis. 2012 Jul;16(7):903-7. doi: 10.5588/ijtld.11.0722. Epub 2012 May 7.

PMID:
22583688
13.

Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.

Aït-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, Clevenbergh P, Dlodlo R, Enarson DA, Enarson P, Ferroussier O, Fujiwara PI, Harries AD, Heldal E, Hinderaker SG, Kim SJ, Lienhardt C, Rieder HL, Rusen ID, Trébucq A, Van Deun A, Wilson N.

Int J Tuberc Lung Dis. 2009 Aug;13(8):927-35.

PMID:
19723371
14.

Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.

Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Engwau FA.

AIDS. 1995 Mar;9(3):267-73.

PMID:
7755915
15.

Treatment of latent tuberculosis infection in HIV infected persons.

Akolo C, Adetifa I, Shepperd S, Volmink J.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD000171. doi: 10.1002/14651858.CD000171.pub3. Review.

PMID:
20091503
16.

Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa.

Nuwaha F.

East Afr Med J. 1998 Sep;75(9):520-7. Review.

PMID:
10493054
17.

Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis.

Zelner JL, Murray MB, Becerra MC, Galea J, Lecca L, Calderon R, Yataco R, Contreras C, Zhang Z, Grenfell BT, Cohen T.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):853-9. doi: 10.1164/rccm.201310-1896OC.

18.

Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children.

Gray DM, Zar H, Cotton M.

Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006418. doi: 10.1002/14651858.CD006418.pub2. Review.

19.

A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.

Fitzpatrick C, Floyd K.

Pharmacoeconomics. 2012 Jan;30(1):63-80. doi: 10.2165/11595340-000000000-00000. Review. Erratum in: Pharmacoeconomics. 2012 Jan;30(1):81.

PMID:
22070215
20.

Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients.

Khawcharoenporn T, Apisarnthanarak A, Manosuthi W, Sungkanuparph S, Mundy LM.

Int J Tuberc Lung Dis. 2012;16(3):336-41. doi: 10.5588/ijtld.11.0402. Epub 2012 Jan 5.

PMID:
22230143

Supplemental Content

Support Center